There are 717 resources available
49MO - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Hiroji Iwata
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
5MO - Evaluation of pathological complete response (pCR) after neoadjuvant chemo-radiation therapy for primary breast cancer (JCOG0306A1)
Presenter: Tadahiko Shien
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
4MO - Machine learning intratumoral and peritumoral magnetic resonance imaging radiomics for predicting disease-free survival in patients with early-stage breast cancer (RBC-01 Study)
Presenter: Wei Ren
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
299MO - Efficacy and safety of entrectinib in an Asian population with <italic>NTRK</italic> fusion-positive (fp) solid tumours or <italic>ROS1</italic>-fp NSCLC
Presenter: Daniel Shao Weng Tan
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
300MO - Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population
Presenter: Masashi Kanai
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
301MO - Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy
Presenter: Afaf Abed
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
302MO - Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
303MO - Single-cell analysis reveals the interaction between M2 macrophages and NK cells underlying immune types associated with cancer immunotherapy response
Presenter: Anlin Li
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
70MO - Efficacy and safety of envafolimab (KN035) in advanced tumours with mismatch-repair deficiency
Presenter: Jian Li
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Webcast
71MO - OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial
Presenter: Her-shyong Shiah
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast